Lisa McClain-Moss

Vice President, Manufacturing • Longeveron

Lisa McClain-Moss joined Longeveron in 2017. She has more than 20 years of experience in the cell and gene therapy space including GMP cleanroom operations. During this time she was involved in the development, manufacturing and scale up of biopharmaceutical products including viral vectors such as vaccinia and retroviruses, H5N1 influenza seed stock for the WHO as well as seed stocks for multiple strains of influenza, rAAV, monoclonal antibodies and cell and tissue expansion and banking. From September 2007 to August 2017 she served as the Director of Manufacturing at Cognate Bioservices. While at Cognate she led manufacturing operations in a GMP environment as well as implementation of new client processes from technology transfer to finished final product. From March 1999 to August 2007, she served at St. Jude Children’s Research Hospital starting with the production of vectors for clinical trials to Therapeutics Production Section Head providing oversight for GMP operations. From 1993 to 1999 she was a microbiologist at C. E. Kord Animal Diagnostic Laboratory providing diagnostic testing for multiple animal species. Lisa McClain-Moss received her BS in Biology/Microbiology from Tennessee Technological University.

Also Speaking

Emma Bjorgum

Vice President, Client Services, DNA • Aldevron

Pete Cotter

Associate Director, Analytical Development • Verve Therapeutics

Arnaud Deladeriere

Director of Process Development • Triumvira Immunologics

Event Info


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.